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Background
Patients with chronic renal failure (CRF) develop second-
ary immunodeficiency as a result of the uremic state and
its metabolic consequences, along with a negative impact
of the dialysis procedure on the immune system. Such
patients are therefore at high risk for septicemia and
other severe infections. In non-vaccinated adults, protec-
tion against Haemophilus influenzae type b (Hib) is
mediated by natural anti-capsular polysaccharide anti-
body. We hypothesized that non-vaccinated adults with
CRF lack protective antibody against Hib, but may
respond to the pediatric Hib vaccine.
Methods
Serum anti-Hib IgG and IgM were studied in 60 patients
with CRF and 40 healthy controls. Thirty-two patients
and 19 controls were immunized with one dose of pedia-
tric Hib vaccine; serum antibody levels were assessed
pre- and 1, 6, 9 months post-vaccine. Functional antibody
activity was studied using a serum bactericidal assay.
Results
Almost 90% of controls, but only 43% of non-vaccinated
CRF patients had protective anti-Hib antibody. Four
week post-vaccination, all but one patient (97%) have
developed protective antibody with a 14-fold increase
(P<0.05); in 29 out of 32 (91%) the antibody exhibited
bactericidal activity. In the majority of patients, protective
antibody persisted 9 months post-vaccine. The vaccine
response did not depend on the age, but was lower in
CRF patients who had type 2 diabetes, COPD, or heart
disease, compared to the rest of the group.
Conclusion
Most adult patients with CRF are at an increased risk of
acquiring invasive Hib disease as they lack protective
antibody. The pediatric Hib vaccine is highly immuno-
genic in this group, with higher response compared to
other vaccines administered to such patients (hepatitis B
and pneumococcal vaccines). This study provides ratio-
nale for the immunization of individuals with secondary
immnunodeficiency against Hib to achieve protective
immunity.
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